Sichuan Kelun-Biotech Biopharmaceutical Past Earnings Performance
Past criteria checks 0/6
Sichuan Kelun-Biotech Biopharmaceutical has been growing earnings at an average annual rate of 43.9%, while the Biotechs industry saw earnings growing at 25.2% annually. Revenues have been growing at an average rate of 24.7% per year.
Key information
43.9%
Earnings growth rate
68.0%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 24.7% |
| Return on equity | -7.3% |
| Net Margin | -9.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 21
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Jun 14Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued
Jan 11Revenue & Expenses Breakdown
How Sichuan Kelun-Biotech Biopharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,877 | -187 | 217 | 1,193 |
| 31 Mar 24 | 1,709 | -354 | 208 | 1,112 |
| 31 Dec 23 | 1,540 | -522 | 199 | 1,031 |
| 30 Sep 23 | 1,523 | -427 | 170 | 1,012 |
| 30 Jun 23 | 1,505 | -333 | 140 | 993 |
| 31 Mar 23 | 1,155 | -440 | 117 | 919 |
| 31 Dec 22 | 804 | -548 | 93 | 846 |
| 31 Dec 21 | 32 | -823 | 91 | 728 |
Quality Earnings: 6990 is currently unprofitable.
Growing Profit Margin: 6990 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6990's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6990's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6990 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.4%).
Return on Equity
High ROE: 6990 has a negative Return on Equity (-7.25%), as it is currently unprofitable.